ABRYSVO® (Respiratory Syncytial Virus Vaccine) CDC Recommendation

Something went wrong

We encountered an unexpected error, we encourage you to try again later.

We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

PP-UNP-USA-5796

Order samples

All samples available online to you are included below. Availability is updated periodically.

PP-UNP-USA-5796

Important Notice

Savings cards will be shipped with Product Samples, if applicable.

Signature

Use your mouse, finger, or stylus to sign below.

Legal Notice

I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.

Your order has been placed

We have received your order and are getting it ready

More to explore

Patient assistance

Download available co-pay cards and patient savings offers across select Pfizer products.

Explore patient assistance

Vaccines

Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.

Explore Vaccines

PP-UNP-USA-5796

Leave ordering?

Changes you have made will not be saved.

This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Log Out

Therapy Areas

Products

Order Vaccines

Order Samples

Order

Materials

Request Samples

Hospital Products

Vaccines

Patient Assistance

Pfizer Oncology Together

Pfizer RxPathways

Pfizer Dermatology Patient Access

Explore Content

Contact

Home

CDC Recommendation

About RSV

About ABRYSVO

Efficacy Profile

Immunobridging

Safety Profile

Patient Profiles

Dosing, Storage, & Reconstitution

Real-World Evidence

Order ABRYSVO

Refer ABRYSVO

Access & Support

Health Plan Coverage

Request a Rep

Vaccine Locator

Materials

Videos

Prescribing Information

Indications

Patient Site

Maternal

ABRYSVO^®: CDC recommended as a single dose for all adults aged 75 and older and for adults aged 50-74 who are at increased risk of severe RSV disease¹*

Risk factors include¹:

Patient attestation is sufficient evidence of the presence of a risk factor. Vaccinators should not deny RSV vaccination to a person because of lack of medical documentation.¹

Over 55% of eligible adults aged 60+ are not vaccinated against RSV^2§

Additionally, ~13 million adults aged 50-59 at increased risk of severe RSV disease are also eligible to be vaccinated with ABRYSVO^3,4

Discuss vaccination today. Don't wait.

Eligible adults can get an RSV vaccine at any time, but the optimal timing is late summer or early fall¹

According to the CDC, RSV vaccines can be coadministered with other adult vaccines. This may include vaccines such as⁵:

Seasonal influenza vaccines

COVID-19 vaccines

Recombinant zoster vaccine

Seasonal influenza vaccines

COVID-19 vaccines

Recombinant zoster vaccine

Pneumococcal vaccines

Td/Tdap vaccines

Pneumococcal vaccines

Td/Tdap vaccines

Available data on immunogenicity of coadministration of RSV vaccines with these and other vaccines are currently limited¹

ABRYSVO can be coadministered with the seasonal influenza vaccine^5,6

Coadministration of ABRYSVO and influenza vaccine, adjuvanted (FLUAD QUADRIVALENT), demonstrated noninferiority compared with sequential administration in adults aged 65 and older⁶

– Fatigue reported in 30% (coadministration), 19.1% (ABRYSVO alone), and 27.1% (flu alone) of participants

– No SAEs were related to vaccination and no additional safety concerns were identified

References

Frailty is a multidimensional geriatric syndrome and reflects a state of increased vulnerability to adverse health outcomes. Although there is no one definition, the Fried frailty phenotype, a frequently used tool, defines frailty as a clinical syndrome with 3 or more of the following symptoms present: unintentional weight loss (10 lbs [4.5 kg] in the past year), self-reported exhaustion, weakness (grip strength), slow walking speed, and low physical activity.¹

Healthcare providers caring for adults aged 60-74 years residing in these communities may use clinical judgement, knowledge of local RSV epidemiology, and community incidence of RSV-associated hospitalization to recommend vaccination for a broader population in this age group.¹

Data from RSVVaxView as of May 7, 2025.²

CDC=Centers for Disease Control and Prevention; kg=kilogram; RSV=respiratory syncytial virus; SAE=serious adverse event; Td=tetanus-diphtheria; Tdap=tetanus, diphtheria, and pertussis.

References

Related Content

Order ABRYSVO

Learn about RSV

Over 55% of eligible adults aged 60+ are not vaccinated against RSV^2§

Additionally, ~13 million adults aged 50-59 at increased risk of severe RSV disease are also eligible to be vaccinated with ABRYSVO^3,4

Stay Informed

Receive Updates About ABRYSVO

Request a Pfizer Sales Representative

Connect Now

View Resources

Stay Informed

Receive Updates About ABRYSVO

Request a Pfizer Sales Representative

Connect Now

View Resources

References:

Centers for Disease Control and Prevention. RSV vaccine guidance for adults. Updated July 8, 2025. Accessed July 10, 2025. https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/adults.html

Centers for Disease Control and Prevention. Weekly RSV vaccination dashboard. Published May 7, 2025. Accessed July 2, 2025. https://www.cdc.gov/rsvvaxview/dashboard/index.html

U.S. Census Bureau. Age and sex composition in the United States: 2023. Updated April 24, 2024. Accessed April 9, 2025. https://www.census.gov/data/tables/2023/demo/age-and-sex/2023-age-sex-composition.html

Centers for Disease Control and Prevention. ACIP recommendations. Published May 15, 2025. Accessed July 10, 2025. https://www.cdc.gov/acip/vaccine-recommendations/index.html

Britton A, Roper LE, Kotton CN, et al. Use of respiratory syncytial virus vaccines in adults aged ≥60 years: updated recommendations of the Advisory Committee on Immunization Practices — United States, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(32):696-702.

ABRYSVO (Respiratory Syncytial Virus Vaccine) Prescribing Information. Pfizer Inc; June 2025.

References:

Centers for Disease Control and Prevention. RSV vaccine guidance for adults. Updated July 8, 2025. Accessed July 10, 2025.
https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/older-adults.html

Centers for Disease Control and Prevention. Weekly RSV vaccination dashboard. Published May 7, 2025. Accessed July 2, 2025.
https://www.cdc.gov/rsvvaxview/dashboard/index.html

U.S. Census Bureau. Age and sex composition in the United States: 2023. Updated April 24, 2024. Accessed April 9, 2025.
https://www.census.gov/data/tables/2023/demo/age-and-sex/2023-age-sex-composition.html

Centers for Disease Control and Prevention. ACIP recommendations. Published May 15, 2025. Accessed July 10, 2025. https://www.cdc.gov/acip/vaccine-recommendations/index.html

ABRYSVO (Respiratory Syncytial Virus Vaccine) Prescribing Information. Pfizer Inc; June 2025.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-A1G-USA-2410

Indications

ABRYSVO is a vaccine indicated for:

active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older

active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age

active immunization for the prevention of LRTD caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV

Please click here for full Prescribing Information.

Important Safety Information

Do not administer ABRYSVO to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of ABRYSVO

The results of a postmarketing observational study suggest an increased risk of Guillain-Barré syndrome during the 42 days following vaccination with ABRYSVO

A numerical imbalance in preterm births was observed compared to placebo in 2 clinical studies. Data are insufficient to establish or exclude a causal relationship between preterm birth and ABRYSVO. To avoid potential risk of preterm birth with use of ABRYSVO before 32 weeks of gestation, administer to pregnant individuals at 32 through 36 weeks gestational age

Appropriate medical treatment must be available in case of an anaphylactic reaction

Syncope (fainting) may occur with administration of injectable vaccines, including ABRYSVO. Procedures should be in place to avoid injury from fainting

Immunocompromised individuals, including those receiving immunosuppressive therapy, may have a diminished immune response to ABRYSVO

Vaccination with ABRYSVO may not protect all recipients

In clinical trials with adults aged 60+, the most commonly reported (≥10%) adverse reactions were fatigue (15.7%), headache (12.9%), pain at the injection site (10.6%), and muscle pain (10.2%)

In clinical trials with adults aged 18-59, the most commonly reported (≥10%) adverse reactions were pain at the injection site (35.3%), muscle pain (24.4%), joint pain (12.4%), and nausea (11.8%)

In clinical trials with pregnant individuals, the most commonly reported (≥10%) adverse reactions were pain at the injection site (40.6%), headache (31.0%), muscle pain (26.5%), and nausea (20.0%)

In clinical trials with infants born to pregnant individuals, low birth weight (5.1% ABRYSVO vs 4.3% placebo) and neonatal jaundice (7.3% ABRYSVO vs 6.9% placebo) were observed

Individuals who received ABRYSVO during pregnancy are encouraged to contact 1-800-616-3791 to enroll in a Pregnancy Exposure Registry.

Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please see full Prescribing Information for ABRYSVO.

Indications

ABRYSVO is a vaccine indicated for:

active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older
active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age
active immunization for the prevention of LRTD caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV

You are now leaving PfizerPro

You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.

PP-MCL-USA-0367